Yervoy with ipilimumab under what conditions?

When does ipilimumab lose exclusivity?

Ipilimumab loses exclusivity in 2025. The primary composition of matter patent expires December 2025.

How do companies challenge ipilimumab patents?

Several biosimilar developers have filed Paragraph IV certifications against ipilimumab patents. Companies such as Amgen, Merck, and Mylan have announced plans to launch biosimilars after patent expiry.

Can biosimilars enter before patent expiry?

No current biosimilar for ipilimumab has received FDA approval or launched. All plans remain subject to patent litigation outcomes.

What price cuts do biosimilars bring?

Biosimilar ipilimumab is expected to offer 20-30% discounts versus the reference product. Early forecasts suggest the reference price will drop 40-50% once multiple competitors enter.

Who makes ipilimumab?

Ipilimumab is made by Bristol-Myers Squibb. It is marketed under the brand name Yervoy.

What regulatory pathways exist for biosimilars?

Biosimilars use the 351(k) pathway under the BPCI Act. They must demonstrate no clinically meaningful differences in safety, purity, and efficacy versus the reference product.

What is the difference between Yervoy and Keytruda?

Yervoy and Keytruda both target immune checkpoints but use different mechanisms. Yervoy blocks CTLA-4, while Keytruda blocks PD-1. They often combine in clinical practice for melanoma and renal cell carcinoma.

What side effects are patients asking about?

Patients report immune-related adverse events such as colitis, hepatitis, endocrinopathies, and skin reactions. These occur more frequently when Yervoy is combined with nivolumab.

When does the Yervoy patent expire?

The Yervoy primary patent expires in December 2025. Secondary method-of-use patents may extend exclusivity into 2027 in some jurisdictions.

When does Yervoy with ipilimumab lose market exclusivity?

Yervoy loses market exclusivity in 2025.